Skip to main content
Premium Trial:

Request an Annual Quote

Celmatix Partners With Onctotest-Teva to Offer Reproductive Health Genetic Test in Israel

NEW YORK (GenomeWeb) – Celmatix said today that it has partnered with Oncotest-Teva, a subsidiary of Teva Pharmaceutical Industries, to make Celmatix's Fertilome genetic test for reproductive health and fertility available in Israel.

The Fertilome test, a multigene sequencing panel, assesses a number of markers that have been associated with conditions that affect fertility, including recurrent pregnancy loss, primary ovarian insufficiency, endometriosis, and polycystic ovary syndrome.

"By gaining an early understanding of their risk of developing conditions that could affect their fertility and reproductive health with the Fertilome test, women in Israel can make more informed choices that may ultimately improve their own outcomes, either by trying on their own or pursuing treatment sooner than they may have otherwise," said Lior Soussan-Gutman, managing director at Oncotest-Teva, in a statement.

Israel's per capita use of in vitro fertilization treatments is high, making it "an ideal market for the first international expansion of the Fertilome test, and we look forward to seeing the impact it will have as women and their doctors make decisions informed by genomic insights," Piraye Yurttas Beim, founder and CEO of New York-based Celmatix, said in the statement.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.